OncoSil Medical (ASX:OSL) reveals results of a study showing...
OncoSil Medical (ASX:OSL) reveals results of a study showing that the addition of OncoSil™ to systemic chemotherapy significantly increases the vascularity of the primary pancreatic tumors and at the same time results in a significant decrease in the size of the tumours.
- This is believed to be the first study in humans demonstrating that the poor vascularity of pancreatic cancer tumors can be increased
- This may consequently increase the concentration of chemotherapy agents within the tumor and further explains the mode of action of OncoSil™
Read the ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/ee563a8f3b7d77fbbb1f2f1f1457b5c7 #
- This is believed to be the first study in humans demonstrating that the poor vascularity of pancreatic cancer tumors can be increased
- This may consequently increase the concentration of chemotherapy agents within the tumor and further explains the mode of action of OncoSil™
Read the ASX announcement: https://app.sharelinktechnologies.com/announcement/asx/ee563a8f3b7d77fbbb1f2f1f1457b5c7 #
OSL
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
